ELEVATED TRIGLYCERIDES:RISK MARKER OR RISK FACTOR?
Details & Video
Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)
View the Links & Resources tab to download the program slides and a transcript, as well as review the list of other podcast platforms where you can listen to this program.
Overview & Objectives
Icosapent ethyl, as shown in the REDUCE-IT study, represents the first agent to improve CV outcomes when added to statin therapy in high-risk patients with elevated triglyceride levels. The clinical benefits of icosapent ethyl are impressive, with demonstrated safety and tolerability, thus creating a major opportunity for the prevention of CV events and mortality in Canada.
However, there are substantial complexities for clinicians to adopt icosapent ethyl in the management of high-risk patients. This podcast discusses the role of elevated triglycerides as a risk marker or risk factor in clinical practice.
|Management challenges for high-risk CV patients in primary care.|
|Are elevated triglycerides associated with CV risk?|
|What is the impact of triglyceride lowering on CV risk?|
|What is the effect of fish oil, Omega-3 FA and IPE on triglyceride levels and CV outcomes?|
Canadian Collaborative Research Network